CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD
CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD
批准号:
10490346
负责人:
Yong Chen
金额:
$75.43万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-30 至 2024-05-31
关键词:
AccountingAddressAgeAlgorithmsAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAreaArtificial IntelligenceBehavioralBrainBrain PathologyCessation of lifeCharacteristicsClinicalClinical InformaticsCognitiveComputer softwareComputing MethodologiesDataDatabasesDementiaDetectionDiabetes MellitusDimensionsDrug DesignDrug ExposureDrug ModelingsElderlyElectronic Health RecordEnvironmental ExposureEventExposure toFDA approvedFunctional disorderGeneticGenetic DiseasesGoalsHealthHealth SciencesHeterogeneityHybridsHyperlipidemiaHypertensionImpaired cognitionInfusion proceduresInterventionInvestmentsKnowledgeLinkLiteratureMachine LearningMedicineMeta-AnalysisMethodsModelingNatural Language ProcessingNeurodegenerative DisordersOntologyOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacy facilityPhasePhase II/III Clinical TrialPreventionProceduresRegression AnalysisReproducibilityResearchRiskRisk FactorsSafetyScoring MethodSemanticsSignal TransductionStatistical MethodsTechnologyTestingTexasUniversitiesbasebiobankcognitive developmentdetection methoddrug candidateeffective therapyefficacy evaluationfollow-upgenetic risk factorhigh dimensionalityindividual patientknowledge graphmild cognitive impairmentmultidimensional datamultimodal datamultimodalitymultiple datasetsnovelnovel therapeuticsphysical inactivityresilienceresponsesocialsocial health determinantssuccess
中文摘要
项目摘要
该提案寻求对发展先进的临床信息学和计算机技术的支持
治疗阿尔茨海默病(AD)和相关痴呆(ADRD)的药物重新定位方法。
拟议的项目直接涉及PAR-20-156中的重点领域,即“开发
使用人工智能/机器学习等计算方法研究新用途
FDA批准的药物或未通过II/III期临床试验的候选药物
对多模式数据的分析。
这项提案的总体目标是开发新的临床信息学和
AD/ADRD药物重新定位的计算方法。具体来说,我们将发展
用于提取药物定位信号的统计方法和本体技术
多维数据(例如,与药房相关的基因数据和生物库数据,历史试验,
和EHR数据)。提出的框架是新颖的,因为它集成了高级统计
基于语义技术的数据驱动可重复性药物推理程序
重新定位AD/ADRD。我们有三个目标:
我们有三个具体目标:
目标1:开发使用多模式数据的信号检测方法(与药房相关
遗传数据、遗传和电子健康记录(EHR)数据和生物库数据)。
目的2:通过历史试验和电子病历评价候选药物的疗效和安全性
数据。
目标3:开发新的语义和自然语言处理(NLP)方法
知识图(KG)构建。
该项目的成功将带来新的计算方法、KG和软件
促进基于多模式数据的AD/ADRD药物重新定位。如果成功,则
提出的方法可以识别新的药物重新定位信号并产生新的假设
对治疗AD/ADRD进行防治干预。我们的项目有希望
识别新的药物重新定位信号。该项目在综合证据方面具有新颖性。
综合方法和使用高级多模式建模的信号检测方法,
它对推进AD/ADRD的预防和治疗具有潜在的变革性。
英文摘要
Project Summary
This proposal seeks support for developing advanced clinical informatics and computational
approaches for drug-repositioning for Alzheimer's disease (AD) and related dementias (ADRD).
The proposed project directly addresses the areas of emphasis in PAR-20-156 to “develop
computational methods such as artificial intelligence/machine learning to investigate new uses
of FDA-approved drugs or candidate drugs from failed Phase II/Phase III clinical trials through
analysis of multimodal data.”
The overarching goals of this proposal are to develop novel clinical informatics and
computational approaches for drug repositioning of AD/ADRD. Specifically, we will develop
statistical methods and ontology technology to extract drug-repositioning signals from
multidimensional data (e.g., pharmacy-linked genetic data and biobank data, historical trials,
and EHR data). The proposed framework is novel because it integrates advanced statistical
inference procedures with semantic technology for data-driven and reproducible drug
repositioning for AD/ADRD. We have three aims:
We have three specific aims:
Aim 1: Develop signal detection methods using multi-modal data (pharmacy-linked
genetic data, genetic and electronic health record (EHR) data, and BioBank data).
Aim 2: Evaluate the efficacy and safety of candidate drugs via historical trials and EHR
data.
Aim 3: Develop novel semantic and natural language processing (NLP) methods for
Knowledge Graph (KG) construction.
The success of this project will lead to novel computational methods, KG, and software for
facilitating drug repositioning for AD/ADRD based on multimodal data. If successful, the
proposed method could identify novel drug repositioning signals and generate novel hypotheses
for prevention and treatment intervention of treat AD/ADRD. Our project holds the promise of
identifying novel drug repositioning signals. This project is novel for integrating evidence
synthesis methods with signal detection methods using advanced multimodal modeling,
and it is potentially transformative for advancing prevention and treatment for AD/ADRD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ClinEX - Clinical Evidence Extraction, Representation, and Appraisal
-
批准号:10754029
-
项目类别:
-
资助金额:$70.88万
-
财政年份:2023
-
负责人:Yong Chen
-
依托单位:
Surrogate Augmented Deep Predictive Learning for Retinopathy of Prematurity
-
批准号:10740289
-
项目类别:
-
资助金额:$48.21万
-
财政年份:2023
-
负责人:Yong Chen
-
依托单位:
Development of Magnetic Resonance Fingerprinting (MRF) to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
-
批准号:10713097
-
项目类别:
-
资助金额:$56.39万
-
财政年份:2023
-
负责人:Yong Chen
-
依托单位:
Development of Magnetic Resonance Fingerprinting in Kidney for Evaluation of Renal Cell Carcinoma
-
批准号:10522570
-
项目类别:
-
资助金额:$46.47万
-
财政年份:2022
-
负责人:Yong Chen
-
依托单位:
Development of Magnetic Resonance Fingerprinting in Kidney for Evaluation of Renal Cell Carcinoma
-
批准号:10707150
-
项目类别:
-
资助金额:$51.61万
-
财政年份:2022
-
负责人:Yong Chen
-
依托单位:
CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD
-
批准号:10476677
-
项目类别:
-
资助金额:$79.4万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
PheBC: bias correction methods for EHR derived phenotype
-
批准号:10471166
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
PheBC: bias correction methods for EHR derived phenotype
-
批准号:10839649
-
项目类别:
-
资助金额:$24.77万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
TRiPOD: Toward Reusable Phenotypes in Observational Data for AD/ADRD - managing definitions and correcting bias
-
批准号:10642888
-
项目类别:
-
资助金额:$78.43万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
TRiPOD: Toward Reusable Phenotypes in Observational Data for AD/ADRD - managing definitions and correcting bias
-
批准号:10279554
-
项目类别:
-
资助金额:$81.17万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
PheBC: bias correction methods for EHR derived phenotype
-
批准号:10624825
-
项目类别:
-
资助金额:$34.22万
-
财政年份:2021
-
负责人:Yong Chen
-
依托单位:
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
-
批准号:10462762
-
项目类别:
-
资助金额:$40.44万
-
财政年份:2019
-
负责人:Yong Chen
-
依托单位:
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
-
批准号:9912379
-
项目类别:
-
资助金额:$45.28万
-
财政年份:2019
-
负责人:Yong Chen
-
依托单位:
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
-
批准号:10251644
-
项目类别:
-
资助金额:$48.49万
-
财政年份:2019
-
负责人:Yong Chen
-
依托单位:
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
-
批准号:10705086
-
项目类别:
-
资助金额:$39.26万
-
财政年份:2019
-
负责人:Yong Chen
-
依托单位:
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
-
批准号:10260605
-
项目类别:
-
资助金额:$39.28万
-
财政年份:2019
-
负责人:Yong Chen
-
依托单位:
Modeling temporomandibular joint disorders pain: role of transient receptor potential ion channels
-
批准号:9595624
-
项目类别:
-
资助金额:$37.72万
-
财政年份:2018
-
负责人:Yong Chen
-
依托单位:
Modeling temporomandibular joint disorders pain: role of transient receptor potential ion channels
-
批准号:9769689
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2018
-
负责人:Yong Chen
-
依托单位:
Modeling temporomandibular joint disorders pain: role of transient receptor potential ion channels
-
批准号:10440366
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2018
-
负责人:Yong Chen
-
依托单位:
Sexual dimorphism of neuroimmune interactions in temporomandibular joint disorders pain: contribution of a newly identified female-specific pain signaling axis IL23/IL17A/TRPV1
-
批准号:10596384
-
项目类别:
-
资助金额:$12.8万
-
财政年份:2018
-
负责人:Yong Chen
-
依托单位:
海外基金